Valuation: Royalty Pharma plc

Market Cap 29.62B 26.47B 24.31B 22.08B 41.5B 2,806B 42.52B 290B 117B 1,481B 111B 109B 4,701B P/E 2026 *
27x
P/E 2027 * 19.1x
Enterprise Value 38.61B 34.5B 31.69B 28.79B 54.1B 3,658B 55.43B 378B 152B 1,931B 145B 142B 6,128B EV / Sales 2026 *
11x
EV / Sales 2027 * 10.1x
Free-Float
72.42%
Yield 2026 *
1.52%
Yield 2027 * 1.63%
1 day-0.18%
1 week+2.53%
Current month-1.16%
1 month+16.17%
3 months+13.64%
6 months+34.22%
Current year+71.84%
1 week 63.48
Extreme 63.485
67.7
1 month 55.13
Extreme 55.13
67.7
Current year 38.29
Extreme 38.29
67.7
1 year 36.03
Extreme 36.027
67.7
3 years 24.05
Extreme 24.05
67.7
5 years 24.05
Extreme 24.05
67.7
10 years 24.05
Extreme 24.05
67.7
Manager TitleAgeSince
Chief Executive Officer 62 1995-12-31
Director of Finance/CFO 44 2009-12-31
Chief Tech/Sci/R&D Officer - 2023-09-20
Director TitleAgeSince
Chairman 62 2020-03-31
Director/Board Member 68 2020-02-10
Director/Board Member 63 2020-06-15
Date Insider Type Main position Quantity % Market Cap. Importance
10/5/26 Sell

Executive/Senior Manager

-4,126 0.0009%
9/30/26 Free

Director

642 0.0001%
9/28/26 Sell

Executive/Senior Manager

-4,126 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
-0.18%+2.53%+76.88%+141.63% 29.62B
-0.11%+10.18%+63.34%+142.88% 1,257B
-1.62%-0.05%+40.93%+77.16% 651B
-0.98%-0.26%+31.17%+99.64% 510B
-1.56%-1.39%+51.02%+64.18% 388B
-2.49%+2.89%+68.26%+40.66% 366B
-0.02%+3.15%+32.47%+55.33% 303B
-0.72%+7.05%+10.34%+32.79% 288B
-0.90%+3.74%+54.56%+73.02% 252B
-1.68%+5.53%+39.80%+106.17% 211B
Average -0.61%+4.41%+46.88%+83.35% 425.63B
Weighted average by Cap. -0.53%+5.28%+47.97%+92.02%

Financials

2026 *2027 *
Net sales 3.51B 3.13B 2.88B 2.61B 4.91B 332B 5.03B 34.3B 13.81B 175B 13.16B 12.87B 556B 3.82B 3.42B 3.14B 2.85B 5.36B 362B 5.49B 37.43B 15.07B 191B 14.35B 14.05B 607B
Net income 1.47B 1.31B 1.2B 1.09B 2.05B 139B 2.1B 14.34B 5.77B 73.25B 5.5B 5.38B 233B 1.77B 1.58B 1.45B 1.32B 2.48B 168B 2.54B 17.34B 6.98B 88.58B 6.65B 6.51B 281B
Net Debt 8.99B 8.04B 7.38B 6.7B 12.6B 852B 12.91B 88.01B 35.43B 450B 33.76B 33.03B 1,427B 9.1B 8.13B 7.47B 6.78B 12.75B 862B 13.06B 89.04B 35.85B 455B 34.15B 33.42B 1,444B
Projected Income Statement - Annual - Royalty Pharma plc
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, Servier's Voranigo, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Pfizer's Nurtec ODT, and Gilead's Trodelvy, and over 17 development-stage product candidates.
Employees
100
Date Price Change Volume
26-11-03 US$66.40 -0.18% 3,146,717
26-11-02 US$66.52 -0.98% 2,873,391
26-10-30 US$67.18 +1.90% 4,662,170
26-10-29 US$65.93 +1.71% 2,450,453
26-10-28 US$64.82 -0.70% 2,414,519
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Royalty Pharma plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
66.52USD
Average target price
65.38USD
Spread / Average Target
-1.72%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Royalty Pharma plc
  1. Stock Market
  2. Stocks
  3. RPRX Stock